Blood mRNA expression signatures derived from unsupervised analyses identify prostate cancers with poor outcome

ABSTRACT: Background: Inter-patient prostate cancer (PrCa) heterogeneity results in highly variable patient outcomes. Multi-purpose biomarkers to dissect this heterogeneity are urgently required to improve treatment and accelerate drug development in PrCa. Circulating biomarkers are most practical for evaluating this disease. We pursued the analytical validation and clinical qualification of blood mRNA expression arrays. Methods: Whole blood samples were collected into PaxGeneTM tubes from PrCa patients: 31 good prognosis patients selected for active surveillance (AS) and 63 advanced castration resistant PrCa (CRPC) patients. RNA was extracted, amplified, biotinylated, and hybridised to Affymetrix U133plus2 microarrays and analysis of genome-wide expression profiles were analysed using Bayesian Late

ORGANISM(S): Homo sapiens

SUBMITTER: Ian Giddings 

PROVIDER: E-GEOD-37199 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress